LAX1 (lymphocyte transmembrane adaptor 1) is a negative regulator of antigen receptor signaling in lymphocytes. As an adaptor protein lacking intrinsic enzymatic activity 1, LAX1 functions as a scaffold for organizing signaling complexes and localizing proteins during T cell receptor (TCR) and B cell receptor (BCR) signal transduction. LAX1 negatively regulates T cell activation and inhibits mitogen-activated protein kinase (MAPK) cascades, thereby suppressing lymphocyte responses to antigenic stimulation. Mechanistically, LAX1 operates through the STAT signaling pathway 2. LAX1 overexpression amplifies STAT1/3 phosphorylation and escalates pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and apoptotic markers (p53, cleaved caspase-3, FAS) 2. A functional malaria-risk variant (rs11240391) shows epistatic interaction with regulatory elements controlling LAX1 expression, with reduced LAX1 expression correlating with severe malaria susceptibility 3. Clinically, LAX1 dysregulation is implicated in multiple diseases. Elevated soluble LAX1 levels correlate with cognitive decline in Alzheimer's disease (r = -0.67) and periodontal destruction (r = 0.71) 2, emerging as a biomarker surpassing established markers like Aβ42. LAX1 is upregulated in aggressive periodontitis 45 and shows reduced expression in pulmonary embolism patients 6. LAX1 is identified as a novel immunotherapeutic target in multiple myeloma 7, representing potential therapeutic opportunities.